Yanina Grant-Huerta - 18 May 2026 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Reporting relationship: Chief Accounting Officer
Issuer ticker: ATRA
Reported as of: 18 May 2026
Net transaction value: -$22,036
SEC form: 4
Accepted by SEC: 20 May 2026, 17:24:23 UTC
Prior SEC filing: 11 Mar 2026
Next SEC filing: 28 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ John Chao, Attorney-in-Fact for Yanina Grant-Huerta

Key filing fact

Yanina Grant-Huerta filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 20 May 2026.

Key facts

This page summarizes Yanina Grant-Huerta's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 May 2026, 17:24.

Change

Previous filing in this sequence was filed on 11 Mar 2026.
Current net transaction value: -$22,036.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002064348 Primary reporting owner

Grant-Huerta Yanina

Relationship: Chief Accounting Officer
Address: C/O ATARA BIOTHERAPEUTICS, INC., 1280 RANCHO CONEJO BOULEVARD, THOUSAND OAKS
Signature: /s/ John Chao, Attorney-in-Fact for Yanina Grant-Huerta
Signature date: 20 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATRA transaction

Common Stock

Sale

Transaction value: $22,036
Shares: -2,414
Change %: -4.6%
Price: $9.13
Shares after: 49,636
Date: 18 May 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.

Footnote F2

Represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $9.12 to $9.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.